Francois Vigneault

Founder at Reflexion Bio
Greater Seattle Area

Francois Vigneault is the founder of Reflexion Bio, Enigma Bio and Pi Bio, building companies at the intersection of biotech and AI to create platforms where large-scale biological data meets machine learning. He previously founded and led Shape Therapeutics as President & CEO, and served as VP Research at Juno Therapeutics. Earlier, he founded AbVitro Inc. as Chief Scientific Officer.

ShapeTX CEO Francois Vigneault Says Generative AI Will Drive Programmable RNA Medicines, Enabling Targeted, Durable Therapies

ShapeTX CEO Francois Vigneault discusses using generative AI to design programmable RNA medicines that repair disease-causing genetic mutations, aiming to make treatments faster, more targeted, and less costly. The conversation covers differences from CRISPR and mRNA vaccines, AI-driven drug discovery, targeted AAV delivery to reduce side effects, and durable RNA editing outcomes.

Juno Therapeutics’ 2013 launch spurred Seattle cell-therapy boom after $300M+ raise and $9B+ 2018 sale to Celgene

Juno Therapeutics, founded in 2013, accelerated cell therapy development by raising over $300 million, going public within a year, and selling to Celgene for more than $9 billion in 2018, and its alumni spawned many Seattle-area biotech startups. The company’s success attracted capital, validated Seattle as a cellular and gene therapy hub, and influenced the region’s biotech entrepreneurship and leadership.

See all 6 stories, episodes and videos about Francois Vigneault.

Organizations

See all 9
  • Reflexion Bio Founder 2025–present · current
  • Enigma Bio Founder 2025–present · current
  • Pi Bio Founder 2025–present · current

Education

  • Université Laval PhD, Molecular and Cellular Biology · 2004–2007
  • Université Laval M.Sc, Molecular and Cellular Biology · 2002–2004
  • Université Laval BSc, Microbiology · 1999–2002

Online